Skip to main content
TipRanks
Go Ultimate75% OFF

BioLargo (BLGO) Stock Price & Analysis

70 Followers

BLGO Stock Chart & Stats

$0.07$0.00(1.49%)
At close: 4:00 PM EST
$0.06$0.08$0.1Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$0.07 - $0.07
52-Week Range
$0.06 - $0.20
Previous Close
$0.07
Volume
N/A
Average Volume (3M)
451.21K
Market Cap
$22.76M
Enterprise Value
$39.76M
Total Cash (Recent Filing)
$2.19M
Total Debt (Recent Filing)
$6.39M
Price to Earnings (P/E)
―
Beta
-0.05
Next Earnings
Nov 18, 2026 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Core Engineering Revenue Growth

Growth in the engineering business provides a durable operating foundation because it is tied to third-party environmental customers rather than only one emerging product. Management’s description of the business as growing and stable supports the potential for recurring service-led revenue and improved scale.

ViaCLYR Commercial Traction And Distribution

ViaCLYR’s use across hundreds of patients and favorable clinician feedback indicate early market validation for an FDA-cleared product. Broad distribution relationships and ongoing health-system evaluations could expand adoption over the next several quarters if approval and implementation processes continue.

PFAS Technology And Strategic Alliance

PFAS treatment addresses a substantial environmental need, while the first commercial installation and trial pipeline provide evidence of progression beyond research. Aquatech’s international reach may improve BioLargo’s ability to pursue larger projects and access customers without building the entire channel alone.

Bears Say

Shrinking Revenue And Severe Operating Losses

The revenue contraction and exceptionally negative operating margins show that the current cost structure remains far ahead of the business’s sales base. Unless commercialization produces sustained growth, continued losses can constrain investment, weaken operating leverage, and increase dependence on external capital.

Heavy Cash Burn And Negative Equity

Persistent cash outflows mean operations are not currently self-funding, while negative equity reduces financial flexibility and resilience. Continued reliance on financing can divert resources from growth initiatives and may create dilution or refinancing pressure if capital needs remain elevated.

Clyra Funding And Commercialization Risk

Clyra offers meaningful growth potential, but its disproportionate contribution to consolidated losses makes execution especially important. Additional fundraising is required before scale is proven, so delays in adoption or reimbursement could prolong cash consumption and increase pressure on the parent company.

BioLargo News

BLGO FAQ

What was BioLargo’s price range in the past 12 months?
BioLargo lowest stock price was $0.06 and its highest was $0.20 in the past 12 months.
What is BioLargo’s market cap?
BioLargo’s market cap is $22.76M.
When is BioLargo’s upcoming earnings report date?
BioLargo’s next earnings report is estimated for Nov 18, 2026 (not yet confirmed), which is in 2 days.
How were BioLargo’s earnings last quarter?
BioLargo released its earnings results on Aug 17, 2026. The company reported -$0.01 earnings per share for the quarter.
Is BioLargo overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does BioLargo pay dividends?
BioLargo does not currently pay dividends.
What is BioLargo’s EPS estimate?
BioLargo’s EPS estimate is -0.01.
How many shares outstanding does BioLargo have?
BioLargo has 334,661,960 shares outstanding.
What happened to BioLargo’s price movement after its last earnings report?
BioLargo reported an EPS of -$0.01 in its last earnings report. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of BioLargo?
Currently, no hedge funds are holding shares in BLGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology